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While the induction of a neutralizing antibody response against HIV remains a daunting goal, data from both
natural infection and vaccine-induced immune responses suggest that it may be possible to induce antibodies
with enhanced Fc effector activity and improved antiviral control via vaccination. However, the specific features
of naturally induced HIV-specific antibodies that allow for the potent recruitment of antiviral activity and the
means by which these functions are regulated are poorly defined. Because antibody effector functions are critically dependent on antibody Fc domain glycosylation, we aimed to define the natural glycoforms associated
with robust Fc-mediated antiviral activity. We demonstrate that spontaneous control of HIV and improved
antiviral activity are associated with a dramatic shift in the global antibody-glycosylation profile toward agalactosylated glycoforms. HIV-specific antibodies exhibited an even greater frequency of agalactosylated, afucosylated, and asialylated glycans. These glycoforms were associated with enhanced Fc-mediated reduction of viral
replication and enhanced Fc receptor binding and were consistent with transcriptional profiling of glycosyltransferases in peripheral B cells. These data suggest that B cell programs tune antibody glycosylation actively
in an antigen-specific manner, potentially contributing to antiviral control during HIV infection.
Introduction
Despite the recent identification of novel monoclonal antibodies
with exceptionally broad neutralization potencies, such neutralizing
responses have been remarkably difficult to induce via vaccination.
However, results from the RV144 vaccine trial, in which protection
from infection was observed in 31% of vaccinees in the absence of neutralizing antibody responses and cytotoxic T cell responses, have reenergized interest in nonneutralizing antibody responses against HIV
infection (1, 2). Beyond neutralization, antibodies are able to mediate a variety of additional effector functions through their capacity
to recruit the innate immune system via Fc receptors (FcRs). Moreover, these antibodies are readily induced early in HIV infection, are
enriched in long-term nonprogressors, and have been shown to provide protection in some models (3–7). However, the specific antibody
characteristics that are associated with enhanced innate immune
activity have yet to be defined. Based on strong genetic and clinical
data from antibody therapeutics, as well as passive transfer and challenge studies in HIV, recruitment of innate immunity is a key factor
in antibody activity in vivo, and, therefore, understanding these characteristics is likely to be important for vaccine development efforts.
Conflict of interest: The authors have declared that no conflict of interest exists.
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The ability of antibodies to recruit innate immune effector cells
is tunable, both in terms of the spectrum of innate immune cells
recruited and the responses induced, ranging from proinflammatory to antiinflammatory depending on the specific FcRs engaged
(8). Several antibody features determine innate immune recruiting
capacity, including antibody titer, affinity, epitope specificity, and
polyclonality, each playing a significant role in effector function
by impacting the geometry and valency of the immune complexes
formed. Because many of the innate immune receptors for antibodies are of low affinity, avid interactions are required to create
multivalent immune complexes to cluster receptors and drive cellular activation (9). Furthermore, because these innate receptors
are expressed on cellular surfaces, spatial arrangement of both
antibody and receptor can have an impact on recognition and
induction of effector functions (10, 11).
Beyond these variable domain features that modulate the
potency of the humoral immune response, antibodies provide
instructions to the innate immune system on how to clear complexed antigens via their Fc domain, providing an additional
level of regulated control over antibody activity. Despite its
nomenclature, the constant domain (Fc) of an antibody possesses a large number of possible states with regard to antibody
potency. The 4 subclasses of IgG (IgG1, IgG2, IgG3, IgG4) vary
somewhat in amino acid sequence but dramatically in their ability to bind innate immune receptors (12). Furthermore, within
a given subclass, the inflammatory properties are more finely
regulated by the specific glycan incorporated on Asn297 of the
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heavy chain, which may be 1 of >30 sugar structures that greatly
influences the affinity between IgG and FcRs or complement
proteins (13). Glycosylation of the Fc domain critically modulates the ability of an antibody to interact with FcRs — permitting bidirectional control and tuning of an antibody’s inflammatory or antiinflammatory activity and selective engagement
of particular innate effector cell activities.
Global antibody glycosylation is altered in numerous disease
states, and these alterations can be highly functionally relevant, as
changes in fucose and sialic acid content can lead to a thousandfold improvement in the antibody-dependent cellular cytotoxicity
(ADCC) activity or, conversely, grant antibodies antiinflammatory
properties (14, 15). While a complete structure/function map of
antibody glycans is lacking, the presence or absence of 3 specific
sugar residues on this N-linked biantennary glycan dramatically
modulates antibody interactions with FcR. Fucosylation of the
mannose core impacts recognition by the activating FCGR3A (14);
sialylation of terminal galactose groups is associated with antiinflammatory activity and reduced FcγR binding (15); and decreased
galactosylation has been implicated in altered interactions with
complement proteins (16). Previous work has shown that chronic
progressive HIV infection is associated with an enrichment of antibodies with agalactosylated (G0) glycans (17), also associated with
autoimmune relapse or flares (18).
The N-linked glycans found at Asn297 can be divided into 3
major classes: (a) G0 structures, which are agalactosylated and
associated with inflammation; (b) G1 structures, which are singly
galactosylated species abundant in healthy individuals; and (c) G2
structures, which possess 2 galactose groups and are associated
with antiinflammatory activity, as they have an increased potential
to be sialylated.
While neutralizing antibody responses emerge in only a fraction of HIV-infected individuals with progressive disease, innate
immune recruiting antibodies, such as those able to elicit ADCC
or, more broadly, antibody-dependent cellular viral inhibition
(ADCVI) emerge in the majority of individuals able to spontaneously control HIV infection (3, 4). These data point to a potential
role of these humoral immune responses in the control of infection. However, little is known about the biophysical properties of
naturally produced antibodies that are able to potently recruit the
antiviral activity of the innate immune system, and less is known
about the degree of antibody glyco-variation in the context of
infection, in which naturally induced glycovariants contribute
most profoundly to antiviral control, or whether glyco-variation
is actively harnessed by the immune system naturally to gain
more effective control of infection. Here we report that while HIV
infection is marked by a bulk antibody shift toward glycans associated with inflammation, spontaneous control of HIV is associated with the production of antigen-specific antibodies with
unique glycoforms superbly tuned to recruit the antiviral activity
of the innate immune system. These data suggest that unique
antigen-specific B cell programs can result in skewed antibody
glycosylation, which may contribute to potent antiviral control
during progressive HIV infection.
Results
Antiviral effector activity of antibodies from HIV-infected subjects. To
begin to define the specific humoral properties associated with
the antiviral activity of innate immune recruiting antibodies, antibodies from patients with differential disease progression were
2184

isolated from plasma and used in an ADCVI assay (19, 20), which
measures both cytolytic and noncytolytic mechanisms of antiviral
activity. In this long-term assay, neutralizing activity against this
tier 2 virus was rare in all subject groups (Figure 1A). However,
antibodies from elite controllers and chronic patients on therapy
elicited the antiviral activity of NK cells to inhibit viral replication
more potently than antibodies from untreated chronic progressors (Figure 1A), implying that low-level viral replication may be
associated with the induction of more potent innate immune
recruiting antibody responses. Additionally, antibodies from viral
controllers induced more robust NK cell responses, with a more
multifunctional profile and greater extent of degranulation (Figure 1B), suggesting that even among subjects with potent inhibition of viral outgrowth, qualitative differences in the innate
immune recruiting capacity of humoral immune responses exist.
In order to account for the mechanism of this differential activity, each of the 3 antibody features known to modulate innate
immune recruiting potential was investigated. No differences were
observed in antibody titer or IgG subclass distribution in either
bulk or HIV-specific antibodies among the different patient populations (data not shown), consistent with previous reports (21),
suggesting that these features could not account for the differences observed in ADCVI activity. In contrast, enzymatic removal
of the glycan from the antibody heavy chain resulted in profound
loss of ADCVI activity (Figure 1C).
Global antibody glycosylation is altered by HIV infection. Thus, to
determine whether specific changes in the distribution of antibody glycan structures could be associated with differences in the
magnitude of ADCVI activity observed among patient groups,
the distribution of glycoforms among the different patient populations was compared. The N-glycans were identified by negative-ion electrospray collision–induced fragmentation (ESI-CID)
mass spectrometry, and their relative proportions were measured
by MALDI-TOF mass spectrometry. The identified glycans were
complex biantennary species, with and without fucose and/or a
“bisecting” GlcNAc (attached to the 4 position of the branching
mannose) and with 0, 1, or 2 galactose residues. The structures
of the glycans are outlined in ref. 22 and Supplemental Figure 1 (supplemental material available online with this article;
doi:10.1172/JCI65708DS1).
Interestingly, we observed a marked shift in the proportion of
agalactosylated glycan species on bulk antibodies in infected subjects compared with that in healthy controls (Figure 1D). This
expansion of G0 glycans occurred at the expense of G1 and G2
class glycans, which, as expected, were prevalent forms in the
healthy HIV-negative controls. Surprisingly, perturbation of
global plasma IgG glycosylation was apparent even during acute
infection, indicating that despite the long plasma half-life of IgG,
infection rapidly impacts the composition, and therefore activity,
of the antibody compartment. Furthermore, although elite controllers durably maintain HIV replication to undetectable levels
and exhibit low-level systemic immune activation (23, 24), the
shift toward agalactosylated glycans was even more pronounced
in these individuals compared with that in both treated and
untreated chronically infected subjects (Figure 1D), suggesting
that unlike the T cell compartment, the B cell compartment in
elite controllers is inflamed (25), resulting in the production of
antibodies with altered glycan composition. However, despite
this change, the increase in G0 could not explain the difference in
ADCVI activity among infected subject groups.
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Figure 1
Effector function and global antibody glycosylation profiles. (A) Antibodies from HIV-infected subjects were examined for their ability to inhibit viral
replication via neutralization (AB) or ability to recruit NK cells as effectors (NK + AB) in an ADCVI assay. Colored bars correspond to unique glycan
structures. (B) NK cell degranulation (dot plot) and cytokine secretion were determined in the ADCVI assay. Pie charts depict the polyfunctional
profile of antibody-mediated NK cell recruitment, including degranulating NK cells (CD107a, 1 function), IFN-γ secretion plus degranulation
(2 functions), or IFN-γ plus TNF-α plus degranulation (3 functions). (C) Glycan dependence of ADCVI activity. Removal of antibody glycan with
the endoglycosidase PNGaseF did not affect neutralization (AB), but ablated viral inhibition resulting from recruitment of NK cells as effectors
(AB+). (A–C) Individual symbols represent each subject tested, and horizontal lines represent the median for a given group of clinically related
subjects. (D) Global plasma IgG glycosylation profiles for all glycan structures (first panel), galactose content (second panel), and fucose content
(third panel). neg, healthy controls; acute, acutely HIV-infected subjects; untx, untreated chronic progressors; tx, treated chronic progressors; ctr,
controllers; F, fucosylated; nonF, nonfucosylated.

Because core α1-6–linked fucose has been implicated in potently
modulating ADCC activity via altered affinity for FCGR3A, an
activating FcγR expressed on NK and other innate cells (14, 26),
we next sought to determine whether lack of fucose was associated with enhanced antibody effector activity and compared the
overall levels of fucosylated and nonfucosylated antibodies among
patient populations. While no difference was observed in the overall frequency of nonfucosylated glycoforms (Figure 1D), deconvolution of the fucosylated and nonfucosylated forms of each of
the G0, G1, and G2 glycan forms revealed some differences in the
frequency of nonfucosylated and branched glycan species among
subject groups (Figure 2).
HIV-specific antibodies exhibit potentiated glycan skewing. To gain
refined insight into the glycan changes specifically associated
with the improved innate immune recruiting activity of antibodies from controllers and treated subjects observed in ADCVI
assays, antigen-specific antibodies were affinity purified, and the
glyco-variation on envelope-specific antibodies, likely involved in
mediating this antiviral function, was determined. Significantly,
the HIV-specific antibody compartment in all 3 patient groups
showed evidence of both inflammation and increased inflammatory activity, exhibiting increases in nonfucosylated, G0, and G1
glycans, and decreases in the less activating, fucosylated G2F and
G1F glycans (Figure 3A). Several subjects exhibited remarkable lev-

els of nonfucosylated HIV-specific antibodies, with greater than
50% of envelope-specific antibodies lacking fucose. Additionally,
there was a trend toward reduced sialylation of the HIV-specific
antibodies (P = 0.09, unpaired t test; data not shown). This shift
toward decreased fucose, galactose, and sialic acid on HIV-specific
antibodies is consistent with a mechanism controlling glycosylation on an antigen-specific basis, rather than simply via global
inflammatory signals.
Despite their significant activity differences, only minor differences in the total galactose or fucose content of HIV-specific
antibodies were observed among subject groups, although agalactosylated glycans were somewhat enriched in the HIV-specific
antibodies of elite controllers (Figure 3B).
However, when comparisons were made as to differences
observed in bulk and HIV-specific antibodies within each subject group, controllers clearly exhibited more robust glyco-variation than chronic progressors (Supplemental Figure 2). Relative
to bulk plasma IgG, the inflammatory nonfucosylated, G0, and
G1 glycoforms were significantly enriched only in elite controllers, and antiinflammatory sialylated and G1F glycoforms were
reduced (Figure 4A), consistent with the increased ADCVI activity
observed in this population and indicative of more robust antigen-specific modulation of glycan in these subjects. Additionally,
when HIV-specific antibody glycans were compared among sub-
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Figure 2
Complete glycan prevalence data for bulk plasma IgG. Relative prevalences (%) of all observed glycoforms in HIV-negative, acute-infected,
treated, and untreated subjects and HIV controllers. Colored underlays represent Tukey’s bars and whiskers. In box-and-whisker plots, horizontal
bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and 90th percentiles.

ject groups, elite controllers possessed significantly lower levels of
G1F, G2F, and bigalactosylated glycans and higher levels of agalactosylated glycoforms on HIV-specific antibodies compared with
untreated chronic progressors (Figure 4B). Because galactosylated
glycoforms have the potential to be sialylated, these alterations in
galactose content may covary with sialylation. Indeed, the trend
toward reduced sialylation observed in controllers is consistent
with such covariance, as can be readily observed in bulk glycans
(Supplemental Figure 3).
Last, relative to uninfected controls, bisected glycans, previously
associated with reduced incorporation of fucose and therefore
exhibiting higher ADCC (27), were enriched in all infected subject
groups, and this enrichment was most profound in treated subjects (Figure 2 and Figure 4B), potentially conferring an alternate
route by which treated patients may regain some capacity to recruit
NK cell–mediated antiviral control (Figure 1A). These data suggest
that progressive HIV disease, marked by high-level viral replication,
either persistently or prior to the initiation of antiretroviral therapy, results in a generalized production of more bisected glycans
on both HIV-specific and total immunoglobulins and may offer an
alternative strategy by which treated chronic progressors explore
glycan structures to enhance ADCVI/ADCC activity.
Antibody galactosylation is associated with antiviral activity. Enrichment
of agalactosylated glycans was associated with increased ADCVI,
whereas bigalactosylated glycans were associated with reduced effector function (Figure 5, A and B, respectively). As a negative control,
neutralization activity did not correlate with any glycan structures
2186

(data not shown). Additionally, ADCVI activity correlated positively
with binding to FCGR3A (Figure 5C). Despite the well-characterized
affinity improvement of nonfucosylated glycans to FCGR3A, the
correlation between ADCVI activity and the abundance of nonfucosylated glycoforms did not reach statistical significance, indicating
that in the context of naturally raised antibodies, galactose levels
may play a more significant role in ADCVI activity than the presence
or absence of fucose. Because reduced galactosylation has not been
associated with potentiated ADCC activity in monoclonal antibodies, the association observed here may reflect concomitant variations in the overall glycan structure, such as altered sialylation, as is
implied by the reduced sialylation of HIV-specific antibodies and a
relationship between galactose and sialic acid content (Supplemental Figure 3). However, others have shown that antibody affinity
purification of IgG on FCGR3A resin favored G0 glycan enrichment
by 10%, whereas both G1 and G2 glycoforms were decreased by 10%
and 20%, respectively (28), consistent with a FCGR3A preference for
G0 antibody glycans. Moreover, to confirm the biophysical interaction of agalactosylated glycans with FCGR3A, antibody samples
from 4 subjects were enzymatically treated with a galactosidase,
resulting in increased G0 glycan and decreased G2 content (Figure
5, D and E). When the ability of these antibodies to bind to FCGR3A
conjugated to a Luminex bead was assessed, the enzyme-treated
pool exhibited significantly higher binding (Figure 5F), whereas no
impact on FcgR1 binding was observed (data not shown), strongly
supporting a preferential physical interaction between FCGR3A and
agalactosylated antibodies.
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Figure 3
HIV-specific antibodies exhibit dramatically inflammatory glycosylation profiles. (A) Relative prevalence of glycans on bulk plasma and antigen-specific antibodies. Statistical analysis was performed using Wilcox matched-pairs signed-rank test. NF, nonfucosylated. **P < 0.005;
***P < 0.0005. (B) Glycosylation profiles of HIV-specific antibodies for all glycan structures (first panel), galactose content (second panel), and
fucose content (third panel).

B cell glycosyltransferase expression is consistent with antibody glycan
alterations. To probe the mechanism underlying differential glycosylation among these subject groups, transcriptional profiling
of glycosyltransferases (GTs) and glycosidases associated with
the antibody glycan was performed. Expression of 16 GTs (Supplemental Table 2) that may be involved in the biosynthesis of
N-linked glycans was determined. When a classifier was trained
with 5-fold cross-validation using this data set, it was able to use
GT expression data to correctly predict whether a subject was

infected or uninfected, averaging better than 85% accuracy. When
applied to further distinguish among infected classes, a classifier differentiated among controllers, untreated subjects, and
HIV-negative individuals with better than 70% accuracy on average
but poorly resolved treated subjects and assigned the majority of
these subjects to the controller class (data not shown). Indeed, the
similarity in GT profiles between treated subjects and controllers
is consistent with the glycosylation data reported here. Untreated
subjects expressed higher levels of GT transcripts associated with

Figure 4
Comparative glycan profiles of bulk plasma and HIV-specific antibodies in each HIV-positive subject class. (A) Significant differences observed
between bulk and HIV-specific antibodies within each subject group. (B) Significant differences observed in HIV-specific antibodies among subject
groups. In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and
90th percentiles. Dots outside of box plots represent outliers. *P < 0.05.
The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013
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Figure 5
Antiviral activity is associated with specific glycoforms and FCGR3A binding. (A) Total agalactosylated (G0 class) glycans prevalence correlates
positively with ADCVI activity. (B) Bigalactosylated (G2 class) glycans prevalence correlates negatively with NK cell ADCVI activity. (C) Bulk
plasma antibody affinity for FCGR3A, measured as Biacore response units, correlates positively with ADCVI activity. (D) Impact of enzymatic
treatment with a galactoside on agalactosylated glycan and (E) bigalactosylated glycan content. (F) Binding of treated and untreated antibody
samples to FCGR3A beads. (A–C and F) Individual symbols represent each subject tested, and horizontal lines represent the median for a given
group of clinically related subjects.

the constitutive components of the glycan, including MGAT1,
MGAT2, and ALG2 (Figure 6A), which may reflect the hypergammaglobulinemia present in this population. Expression of the
fucosyltransferase responsible for core fucosylation, FUT8, was
decreased in controllers and treated progressors relative to that in
untreated progressors (Figure 6B), while the fucosidase, FUCA2,
was enriched in controllers and untreated subjects (Figure 6B).
While the biological relevance of FUCA2 expression in B cells is
unproven, these expression patterns are nonetheless consistent
with the observation of decreased fucosylation in HIV-infected
subjects. Expression changes in galactose transferases were also
observed (Figure 6C), with HIV-infected subjects exhibiting significantly lower expression of one or both galactose transferases
studied. Overall, the alterations in GT expression were consistent
with the hypergammaglobulinemia (Figure 6A), decreased fucosylation (Figure 6B), and decreased galactosylation (Figure 6C)
observed in the antibodies of infected subjects. Further study of
GT expression in HIV-specific B cells is likely to yield additional
insight into B cell modulation of antibody activity.
Discussion
The complexity of antibody functions mediated through FcRs belies
the ability of the humoral immune system to tightly regulate recruitment of innate effector cells to rapidly clear the antigens to which
they are bound. While only a subset of individuals with progressive
HIV infection are able to mount neutralizing antibody activity, individuals that spontaneously control HIV infection generally produce
antibodies with a robust capacity to recruit the antiviral activity of
the innate immune system, suggesting that innate immune recruiting antibodies, rather than neutralizing antibody responses, may
2188

be vital in antiviral control. Therefore, efforts to better understand
the characteristics of naturally induced innate immune recruiting
antibodies may provide novel information to help improve the functional quality of vaccine-induced antibodies. Significantly, antibodies from HIV-infected subjects vary dramatically in their ability to
recruit the cytotoxic functions of NK cells, and these differences
could not be attributed to either titer or IgG subclass. Intriguingly,
suppression of viral replication, whether spontaneous or mediated
by antiretroviral therapy, was associated with more potent effector
activity, indicating that specific and global inflammatory cues likely
have a complex role in determining antibody glycosylation.
While alterations in antibody glycosylation are present in
numerous disease states, we were surprised to find here that (a)
despite its long plasma half-life, global plasma IgG glycosylation
was significantly perturbed during acute infection; and (b) antibodies from elite controllers, whose plasma generally does not
exhibit traditional markers of inflammation, exhibited the most
profound IgG glycan skewing. The impact of these global glycosylation changes on humoral immunity is unknown. Furthermore,
we found that glycosylation patterns were different between bulk
plasma antibody and HIV-specific fractions, indicating that the
immune system has evolved means to both globally and specifically, in an antigen-dependent manner, shift antibody function.
Defining the signals responsible for the modulation of glycosylation in both global and disease-specific antibody repertoires is
likely to be of great clinical relevance in disease states in which
antibodies play either protective or pathological roles.
Given the dramatic activity differences in cell-based assays, glycan modulation among subject groups was surprisingly small,
leading to the possible conclusion that subtle glycan modulation
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Figure 6
Transcriptional profiling of GTs and glycosidases relevant to IgG glycans in peripheral B cells. (A) GTs involved in synthesis of all antibody glycans, the MGAT1 and MGAT2 enzymes involved in the conversion of oligomannose to complex N-glycans and ALG2 involved in initiating N-linked
glycosylation, were upregulated in untreated subjects. (B) Fucosyltransferase FUT8 expression was increased in untreated progressors, while
fucosidase FUCA2 was increased in controllers and untreated progressors. (C) Galactose transferases B4GALT1 and B4GALT3 were decreased
in HIV-infected subjects. The y axis represents transcript expression relative to a housekeeping gene. Individual symbols represent each subject
tested, and horizontal lines represent the median for a given group of clinically related subjects. *P < 0.05; **P < 0.005; ***P < 0.0005.

may lead to significant activity differences, with minor glycan species capable of playing a significant role in overall antibody effector function. This possibility is consistent with other studies in
which minor glycan species have been found to be responsible for
overall antibody activity (29). Alternatively, because the experimental methods used here could not simultaneously define either the
subclasses associated with each glycan structure or assign both Fc
glycans present on a given antibody molecule, it is possible that
if this level of resolution were possible, perhaps more dramatic
differences among subject groups would have been apparent. Furthermore, while some generally applicable principles regarding the
effector function of glycans have been determined in studies of
monoclonal antibodies, such as the role of fucose in modulating
ADCC activity, the context in which these saccharides are present
may be important — with fucose having a greater or lesser effect in
the context of G0, G1, G2, or bisected glycan chains.
Despite these limitations, a clear association between galactose
levels and ADCVI activity was observed. This association was
surprising in that increased galactosylation has tended to drive
better ADCC in recombinantly produced monoclonal antibodies
(26). While there are a number of plausible explanations for this
discrepancy, the simplest is that, in naturally produced antibodies, galactosylation covaries with differential sialylation, as sialic
acids are incorporated via linkages to terminal galactose groups.
Recombinant monoclonal antibodies, typically secreted from animals, and non–B cell types may not exhibit the same covariation
in galactose and sialylation or may differ in isomerization patterns
due to inherent differences in GT expression or antibody trafficking and processing in the endoplasmic reticulum. Similarly, covariation of oligomannose intermediates may be a confounding factor
in studies of recombinant antibodies, whereas these high mannose
forms known to have improved ADCC activity are extremely rare
in naturally expressed human antibodies. Alternatively, antibody
galactosylation has recently been associated with antiinflamma-

tory activity following FcgR ligation via interactions with additional binding partners (30). However, here we show that beyond
associated minor glycan species changes, agalactosylated antibodies themselves may have an enhanced capacity to bind to FCGR3A,
potentially resulting in more potent ADCC/ADCVI activity.
Alterations in antibody glycosylation ultimately result from
altered glycan biosynthesis on a cellular level, likely due to
changes in the expression of enzymes involved in N-linked glycan biosynthesis or due to the rate of antibody transit through
the endoplasmic reticulum prior to secretion. HIV infection was
associated with significant shifts in the expression of several GTs
and glycosidases, which are involved in multiple steps of glycan
synthesis, consistent with the production of a larger population
of agalactosylated antibodies. Moreover, elite controllers exhibit
an enzyme expression profile marked by changes in enzyme
expression, likely resulting in the production of a larger fraction
of nonfucosylated antibodies, suggesting that distinct inflammatory cues or differences in the mechanism of B cell priming
or education may result in the skewed expression of the enzymes
involved in tuning antibody Fc effector functions. Ultimately,
understanding the mechanism by which these enzymes are regulated, particularly in HIV-specific B cells, may provide opportunities to begin to define novel strategies by which vaccines could
elicit more antiviral innate immune recruiting antibodies.
Overall, we believe these studies highlight the first example of
skewed glycosylation of disease-specific antibodies in HIV infection and, more importantly, that these shifts are regulated by
both general inflammatory cues as well as antigen-specific fine
adjustments, resulting in the production of antibodies with
enhanced effector functions. However, whether antibody glycosylation can be regulated permanently in memory B cells or
long-lived plasma cells provides an exciting prospect for future
vaccine efforts aimed at potentiating the functional capacity of
vaccine-induced antibody responses.
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Subjects. A total of 90 subjects, including 10 acute/early HIV-infected individuals, 24 chronically infected individuals off therapy, 24 chronically
infected subjects receiving treatment, 22 controllers, and 10 HIV-negative
individuals, were recruited for antibody analysis studies. The 10 acute/
early HIV-infected subjects, defined as p24-antibody negative or Western
blot indeterminate, were recruited within the first 5 months of infection
and were followed longitudinally in the absence of antiretroviral therapy.
GT expression analysis was conducted on a second group of 61 subjects,
and subject characteristics for each study group are reported in Supplemental Table 1. The local and Massachusetts General Hospital Institutional Review Boards approved the study, and each subject provided written informed consent for participation in the study.
Antibody purification. Bulk IgG was purified from 200 μl of plasma using
a Melon Gel IgG Purification Kit (Thermo Scientific). Briefly, the resin
was washed twice with Melon Gel buffer and incubated with diluted
plasma on a rotator for 5 minutes to allow for the binding of plasma proteins. Antibodies were spun through the resin, and the concentration was
calculated using a Nanodrop spectrophotometer (Thermo Scientific).
Following IgG purification, HIV-specific antibodies were affinity purified using a custom amino-link (Pierce) gp120 resin. Each microcolumn
was conjugated with 100 μg gp120 (Immune Technologies) according
to the manufacturer’s protocol. Conjugation efficiency was determined
to be at least 50% for all columns prepared. Each column was used to
process IgG from a single subject. Briefly, purified subject IgG (2–10 mg)
was incubated with the resin prior to washing and low pH elution. Eluted
antibodies were immediately neutralized. Analysis was performed to verify that brief acid exposure did not alter glycan composition and that
gp120 was not released from the resin. Antibodies titers were determined
by ELISA as described previously (21), and enrichment of gp120-specific
antibodies was confirmed by ELISA.
ADCVI assay. The capacity of plasma antibodies to recruit the antiviral
activity of NK cells and suppress viral replication was measured using an
ADCVI assay (20). Briefly, PBMCs from an HIV-1–negative donor were
cultured with a CD3/8 bispecific antibody (0.3 μg/ml) for 4 days in the
presence of 50 U/ml IL-2 (NIH) to produce activated CD4+ T cells. On
the fourth day, the CD4+ T cells were infected at an MOI of 0.01 with an
R5 viral strain (JRCSF). In parallel, NK cells were purified from the same
donor using negative selection (RosetteSep; Stem Cell Technologies).
The purified IgG was added to the CD4+ T cells (10 μg/ml) in duplicate,
and NK cells were added to one of the duplicate wells. The supernatant
was collected on day 7, and the level of inhibition was quantified as the
difference in p24 produced in wells containing antibodies/effectors compared with wells containing CD4+ T and NK cells alone. Each data point
represents the average of 3 independent experiments using different
autologous effector/target donors. Supplemental Figure 4 presents the
reproducibility of this ADCVI assay across multiple donors assessed on
different days. To reduce inhibition due to NK cells alone, only KIR3DS1–
donor cells were used (31). A subset of antibody samples were treated
with PNGaseF (New England Biolabs) to remove N-linked glycans, as
previously described (32). The presence of inactivated PNGaseF did not
affect the ADCVI assay results.
Antibody-induced NK cell degranulation assay. Intracellular cytokine staining was used to determine whether the IgG purified from the plasma of
acutely infected subjects exhibited a differential capacity to promote NK
cell cytokine secretion and/or degranulation as a surrogate for NK cell
cytolysis (19). Briefly, activated CD4+ T cells were prepared as described
for the ADCVI assay. In parallel, NK cells were purified by negative selection and cultured in media supplemented with 50 U/ml IL-2 for 4 days.
On day 4, the CD4+ T cells were infected with a VSV-pseudotyped R5
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virus (JRCSF) for 2 hours and then cultured for an additional 2 days.
On day 6, CD4+ T cells were then counted and split into duplicate FACS
tubes. The purified IgG was added at 50 μg/ml to each duplicate tube,
and NK cells were added to one of the tubes at an effector to target ratio
of 1:1. Anti-CD107a-PECy5 (20 μl/ml; BD Biosciences), Brefeldin A
(0.5 μg/ml; Sigma-Aldrich), and Golgi-stop (0.3 μg/ml; BD Biosciences)
were added, and the tubes were incubated for 6 hours at 37°C. NK cells,
either alone or in the presence of uninfected CD4+ T cells, were used as a
negative control, and NK cells stimulated with PMA/ionomycin (1 μg/ml)
were used as a positive control. Following incubation, the samples were
stained with anti-CD3-Pacific Blue, anti-CD56-PE-Cy7, and anti-CD16APC-Cy7 (BD Biosciences) to define NK cells; fixed; permeabilized (FIXA/B, Caltag/Invitrogen); and then stained with anti-IFN-γ-FITC and
anti-TNF-α-Alexa 700 (BD Biosciences). The cells were then resuspended
in 100 μl 2% paraformaldehyde-PBS, and data were acquired on a BD
LSRII. The proportion of degranulated or cytokine-secreting NK cells
was then calculated as follows: (percentage of cells that were positive
for the marker of interest / percentage of cells that responded to PMA/
ionomycin) × 100. The background level of NK cell activation by HIV-infected autologous cells was subtracted from the experimental values, and
a response was considered positive if the proportion of CD107a-expressing or cytokine-positive cells following stimulation was at least 2-fold
greater than the mean of the no plasma controls. Supplemental Figure
5 presents the correlation of ADCVI assay results presented in this study
with NK cell degranulation and cytokine secretion.
FcγRIIIa/antibody affinity assays. Surface plasmon resonance was used to
measure the strength of the antibody-FCGR3A interaction. Wells on a Biacore CM5 research-grade chip were coated with 5 μg recombinant FcγRIIIa
or a control protein (Staphylococcal enterotoxin B, Sigma-Aldrich). Purified
bulk IgG was diluted to a concentration of 0.2 μg/ml, and the binding
affinity was calculated as the peak relative units of binding for each antibody sample normalized to control protein binding. Binding of the monoclonal IgG1 b12 antibody was used as a positive control, and the mutant
LALA b12 variant (provided by Dennis Burton, The Scripps Research Institute, La Jolla, California, USA), with impaired FcR binding activity, was
used as a negative control.
Generation of G0 antibodies. To generate hypogalactosylated antibody, IgG
(10 ml of 0.250 mg/ml) was isolated from healthy donor plasma using
protein G beads (GE Healthcare) and incubated overnight at 37°C in
neuraminidase (500 U/ml, New England Biologicals), as per manufacturer
instructions. The solution containing desialyated IgG was supplemented
with NaCl to a final concentration of 100 mM and incubated overnight at
37°C with β-1,4-galactosidase (20 U/ml, New England Biologicals) 3 times.
Galactose content was determined by HPLC (33).
FCGR3A binding activity. A customized Luminex assay was developed in
which recombinant FCGR3A was covalently conjugated to magnetic beads
and incubated in antibody over a dilution range, and bound antibody was
quantified with phycoerythrin-conjugated mouse anti-human IgG, in an
adaptation of a previously described protocol (34). Binding of a series of Fc
domain amino acid point mutants was used to validate that signal in this
assay correlated with binding affinity (data not shown).
Glycan analysis by mass spectrometry. Enzymatic release of N-linked glycans
was performed according to the method of Küster (35). Oligosaccharides
were released from bands containing approximately 10 μg target glycoprotein that was excised from Coomassie blue–stained reducing SDS-PAGE
gels, washed with alternating water and acetonitrile, and dried in a vacuum
centrifuge, followed by rehydration with 100 units/ml of PNGase F (New
England Biolabs) and incubation for 12 hours at 37°C. The enzymatically
released N-linked glycans were eluted with water. Aqueous solutions of the
glycans were cleaned with a Nafion 117 membrane.
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Positive-ion MALDI-TOF mass spectra were recorded with a Shimadzu
AXIMA TOF2 MALDI-TOF/TOF instrument (Shimadzu-Kratos) fitted with
delayed extraction and a nitrogen laser (337 nm). The acceleration voltage
was 20 kV; the pulsed extraction was optimized for m/z 1,700. Samples were
prepared by adding 0.5 μl of an aqueous solution of the sample to the matrix
solution (0.3 μl of a saturated solution of 2,5-dihydroxybenzoic acid in acetonitrile) on the stainless steel target plate and allowing it to dry at room temperature. The sample/matrix mixture was then recrystallized from ethanol.
Negative-ion ESI mass spectrometry was performed with a Waters Synapt
G2 quadrupole-ion mobility-TOF (Q-IMS-TOF) mass spectrometer (Waters
MS Technologies) for samples with sufficient material remaining. Sample
were dissolved in 1:1 (v/v) water/methanol (8 μl), 1 μl of a 1 M solution of
ammonium phosphate was added, and the samples were spun at 3,000 g in
a bench centrifuge for 1 minute. Sample introduction into the mass spectrometer was via Waters thin-wall nanospray capillaries. The ion source temperature was maintained at 120°C, and fragmentation was performed, with
argon, in the instrument’s transfer cell. The collision energy was adjusted
according to the mass of the parent ions to give an even distribution of
fragments across the mass range. Instrument control and data processing
were performed with Waters MassLynx software, version 4.1. Fragmentation
spectra were interpreted as described by Harvey et al. (36–39).
GT expression profiling. CD3–CD19+CD27+ cells were separated by magnetic separation (Miltenyi Biotec), and the transcriptional profile of these
peripheral B cells was determined using Illumina HumanHT-12 whole-genome expression BeadChips. Briefly, following incubation with magnetic
microbeads, cells were thoroughly washed, and a minimum of 5 × 105
pure B cells from each subject was resuspended in RNA later. RNA was
extracted using the Qiagen RNeasy Kit (Qiagen). Then, 200 ng of total
RNA was amplified using the Ambion Illumina TotalPrep RNA Amplification Kit, and 1,500 ng of the amplified cDNA was hybridized overnight
to the BeadChip. After a series of washes, BeadChips were read using the
Illumina BeadStation. The resulting images were analyzed using the Illumina BeadStudio software, and internal controls were evaluated for each
sample to quality control the data. Data from the samples that passed
chip processing quality control was exported and normalized, and expression for a set of 16 GTs with possible activities relevant to the antibody
N-linked glycan, as described by the Korean Encyclopedia of Genes and
Genomes (KEGG) database (40, 41), was extracted. Data presented represent expression amplitude (log2).
Subject classification analysis. Three commonly used methods were selected
to analyze the information content of the GT expression data set in terms
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